Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Bevenopran in Renal Impairment
NCT02508740Phase 1Terminated
- Sponsor
- Merck & Co.
- Start
- Sep 2013
- Primary completion
- Dec 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of bevenopran in opioid-induced constipation (OIC) (5 arms), sponsored by Merck & Co. Primary endpoint: Plasma concentrations of bevenopran. Started Sep 2013; status: terminated.
02
Drugs
bevenopran
03
Conditions
opioid-induced constipation (OIC)
Beyond the preview
Go deeper on NCT02508740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02508740.